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Irinotecan, 7-ethyl-10[4-(1-piperidino)-1-piperidino]carbonyloxy-
camptothecin (CPT-11), is a topoisomerase I (topo I) inhibitor
commonly used in the treatment of colorectal tumours, and
promising results have been recently reported in metastatic disease
(Rothenberg et al, 1996; Rougier et al, 1997). CPT-11 is a prodrug,
which differs structurally from other camptothecin derivatives by
a bulky piperidino side chain located at the C-10 position of the
camptothecin molecule (Kunimoto et al, 1987). This piperidino
group must be cleaved enzymatically by a carboxylesterase to
form SN-38, which is the active metabolite (Tanizawa et al, 1994).
The anti-tumour activity of CPT-11 is, therefore, dependent on
both its activation by the CPT-11-converting carboxylesterase
(CPT-CE) and the cellular level of the target enzyme topo I.
Carboxylesterases are a family of ubiquitary enzymes that react
with many substrates such as p-nitrophenyl acetate (p-NPA) and
nitrophenyl butyrate. They are present in vertebrates and classified
by substrates for which they have high affinity and the specific
compounds that inhibit their activity (Miller et al, 1980; Satoh &
Hosokawa, 1995). The CPT-CE has been characterized in liver
microsomes (Rivory et al, 1996; Slatter et al, 1997), and showed
the relative inefficiency for CPT-11 transformation in the liver. In
fact, the low efficiency of carboxylesterases seems to be a general
feature of the human enzymes, and the interspecies comparison of
the carboxylesterases with a panel of substrates, demonstrated that
the human enzymes were among the less efficient (Hosokawa
et al, 1990). However, a specific CPT-CE was isolated from rat
serum (Tsuji et al, 1991). These authors demonstrated that the
CPT-CE exhibited different enzymatic properties compared to
the other carboxylesterases and that the Km was different between
p-NPA and CPT-11. The conversion of CPT-11 into SN-38 has
been studied in a wide variety of tissues, cell lines and purified
enzyme preparations in vitro (Jansen et al, 1997; Kawato et al,
1991; Ogasawara et al, 1995; Rivory et al, 1996; Satoh et al, 1994;
Slatter et al, 1997; Tsuji et al, 1991; van Ark-Otte et al, 1998). The
sensitivity of proliferating tissues or cell lines to cytotoxic effects
of CPT-11 may be related to their carboxylesterase levels (Kawato
et al, 1991; Ogasawara et al, 1995). A decreased conversion of
CPT-11 to SN-38 has been reported in vitro in resistant ovarian
and non-small-cell lung cancer cell lines (Niimi et al, 1992;
Ogasawara et al, 1995). However, little is known about CPT-CE
activity in human tumours; the use of CPT-11 as a substrate in our
study, insured the specific determination of CPT-CE among the
overall carboxylesterases.
CPT-11 is a topo I inhibitor. Topo I is a nuclear enzyme that
regulates the torsional strain of the DNA. Topo I enzymatic
reaction involves the binding of topo I to DNA, the cleavage of
one strand of DNA, the passage of the intact strand through topo
I–DNA complex, and the resealing of the cleaved strand, without
modification of the DNA sequence. SN-38 stabilizes the topo
I–DNA complex or ‘cleavable complex’, thereby maintaining a
single-strand DNA break. The collision between such an SN-38
stabilized cleavable complex and a DNA replication fork converts
the single-strand DNA break to a double-strand break, which is
highly deleterious (Creemers et al, 1994; Slichenmyer et al, 1993).
The cytotoxicity of topo I inhibitors seems to be related to the level
of topo I in cells: cells expressing high levels of topo I are hyper-
sensitive to topo I inhibitors, while a decreased level of the target
enzyme could be a factor of resistance to camptothecin derivatives
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(Knab et al, 1993; Benedetti et al, 1993; Takano et al, 1992). High
topo I levels have been reported in colon (Giovanella et al, 1989;
Husain et al, 1994; McLeod et al, 1994), prostate (McLeod et al,
1994), ovarian carcinomas (Codegoni et al, 1998; Cornarotti et al,
1996; van der Zee et al, 1994) and lymphomas (Potmesil et al,
1988). Several studies (Giovanella et al, 1989; Husain et al, 1994;
McLeod et al, 1994) emphasized a positive ratio of topo I activity
between tumour and adjacent normal tissue in colon carcinomas,
associated with a wide interpatient variability.
In the current study, the activities of CPT-CE and topo I were
measured simultaneously in the tumour and adjacent normal tissue
of 59 patients with colorectal cancer to assess the interpatient vari-
ability, the possible correlations between the various tissues and
the identification of demographic and pathological factors that
influence drug activation and efficacy.
MATERIALS AND METHODS
Chemicals
CPT-11 and SN-38 were provided by Rhône Poulenc Rorer labora-
tories (Vitry sur Seine, France).
Patients
Evaluation of CPT-CE and topo I activities was conducted in 59
patients undergoing surgery for colon or rectal carcinoma. The
surgical procedure was for initial resection in the majority of
patients (51 patients), while six patients underwent hepatic lobec-
tomy for solitary colorectal metastases and two patients had simul-
taneous tumorectomy and partial hepatectomy. This study was
conducted after obtaining informed consent from patients.
Immediately after resection, portions of non-necrotic tumour
and adjacent normal tissue (> 5 cm from tumour) were excised by
a pathologist and frozen in liquid nitrogen. Samples were stored at
–80°C until analysis of enzyme activity. All analysis of frozen
samples were performed within 2 months. We have verified that
storage up to 6 months did not affect CPT-CE and topo I activities.
Moreover, in seven tumours, enzymatic activities were determined
in two independent portions of the resection to check the homo-
geneity in enzyme activities. No significant difference was
observed.
The influence of tissue enzyme activities in response to CPT-11
therapy was not evaluated in this study because of the small
number of individuals who received uniform post-operative
therapy within each Dukes’ stage.
Analysis of enzyme activities
CPT-CE activity
Tumour and normal tissues were homogenized in 35 mM sodium
phosphate buffer pH 7.5. The homogenate was centrifuged at
20 000 g for 30 min at 4°C. Cytosolic protein concentration was
determined with the Bradford method (Bradford, 1976).
Preliminary study was made on pooled tumoural cytosols to
optimize CPT-CE determination. Different concentrations in
substrates (1–20 mM CPT-11), in protein concentrations (0.5–
4 mg ml–1) and incubation times (5–120 min) have been tested. A
plateau of SN-38 formation was obtained after 30 min incubation;
a linearity of the enzymatic reaction was observed as a function of
the protein concentration in the presence of an excess in substrate
(5 mM) (data not shown). Moreover, in case of very low (< 1 pmol
min–1 mg protein–1) or very high activity (> 5 pmol min–1 mg
protein–1) in tumours, a kinetic study (4 points) of the enzymatic
activity was again performed with either a higher or a lower
protein concentration.
The CPT-CE activity was then carried out by pre-incubating
80 ml of cytosolic proteins (3 mg ml–1) for 5 min at 37°C in
Eppendorf tubes and then 5 mM CPT-11 (20 ml) was added for an
additional 60 min (Rivory et al, 1996). The reaction was stopped
by addition of 100 ml of an ice-cold mixture of acetonitrile, water
and 0.1 N hydrochloric acid (HCl) (3:3:3, by vol). After centrifu-
gation at 4°C for 15 min at 400 g, the supernatant (150 ml) was
recovered and 50 ml aliquots were analysed for SN-38 concentra-
tion. SN-38 produced during the incubation was measured by the
high-performance liquid chromatography (HPLC) method of
Rivory and Robert (Rivory and Robert, 1994). Briefly, separation
was performed on a Nucleosil C18 column (5 mm, 300 mm ´ 3.9
mm), eluted with a mobile phase consisting of 0.075 M ammonium
acetate buffer (pH 6.4)-acetonitrile (60:40, v/v) containing tetra-
butylammonium phosphate (PIC A Waters, Saint Quentin en
Yvelines, France) at a final concentration of 5 mM. Detection of
SN-38 was carried out with a Shimadzu fluorometer with excita-
tion and emission wavelengths biased towards SN-38 detection at
380 and 540 nm respectively. Standards were prepared from a
100 mg ml–1 stock solution of SN-38 diluted serially in a mixture of
acetonitrile, water and 0.1 N HCl (3:3:3, by vol). Standard curves
were constructed for each batch of samples and were linear from
2.5 to 25 pmol SN-38 ml–1. CPT-CE activity was expressed as
pmol min–1 mg protein–1.
DNA topo I activity
Tumour and normal tissues were homogenized in 0.01 M
phosphate-buffered saline (PBS) buffer pH 7.4. Crude nuclear
extracts were prepared as described previously by Deffie et al,
(1989). Briefly, the homogenate was washed twice with cold
nuclear buffer (NB) (2 mM K2HPO4, 5 mM magnesium chloride
(MgCl2), 150 mM sodium chloride (NaCl), 1 mM EDTA and
0.1 mM dithiothreitol (DTT), and resuspended in 1 ml of NB
containing 0.35% of Triton X-100 and 1 mM phenylmethyl-
sulphonyl fluoride (PMSF). It was kept on ice for 10 min, washed
twice with cold NB. Nuclear proteins were extracted for 1 h at 4°C
with cold NB containing 0.35 M NaCl. After centrifugation at
18 000 g for 10 min at 4°C, the supernatant was added with
50% glycerol. The protein concentration was determined using
bicinchoninic acid (Smith et al, 1985).
The DNA topo I activity was determined according to Jaxel
et al (1989) with the use of a standard curve of purified topo I
(TopoGen Inc, Colombus, OH, USA). The reaction mixture
contained 50 mM potassium chloride, 5 mM MgCl2, 0.1 mM
EDTA, 15 mg ml bovine serum albumin (BSA), 10 mM Tris-HCl
pH 7.5, 0.5 mM DTT, 0.5 mg pKS plasmid, and either serial
dilutions of nuclear extract or dilutions of purified topo I (0–5 U)
in a final volume of 20 ml. After 10 min at 37°C, the reaction was
stopped by addition of 1% sodium dodecyl sulphate (SDS), 20 mM
EDTA, 0.5 mg ml–1 proteinase K, and incubation was carried out
for an additional 30 min. Dye solution (2.5 ml of 10 mM Na2HPO4,
0.3% bromophenol blue, 16% Ficoll) was then added to samples
which were electrophoresed in 1% agarose gel in Tris borate
EDTA migration buffer at 30 V overnight. Gel was stained with
ethidium bromide and visualized in a UV transilluminator. Gel366 S Guichard et al
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pictures were analysed by Photostyler and Optimas softwares.
Topo I activity of samples was calculated from the standard curve
of topo I established for each experiment. Results were expressed
as units of topo I activity per mg protein.
Statistical analysis
Statistical tests were performed after verification of the gaussian
distribution of the population for the different parameters studied.
Comparisons were carried out after controlling for homogeneity of
the variances. The comparisons of averages used two-sided t-test,
while the comparisons between the tumour and the normal tissue
used paired t-tests. A c2 test was performed to evaluate the distrib-
ution of patients within different subgroups. The correlation
between two parameters was calculated and its significance was
evaluated by a t-test. The significance level used for all tests was
0.05.
RESULTS
Characteristics of the population
Enzyme activities were assessed in tissue from 59 consecutive
patients (22 male and 37 female). The median age of the patients
was 71 years and ranged from 30 to 85. Liver metastases and adja-
cent normal liver were also obtained from eight patients. The
tumours were preliminary Dukes’ stage A (n = 10), B (n = 15) and
C (n = 28).
CPT-CE activity
The distribution of CPT-CE activity in tumour and normal colon
tissues is illustrated in Figure 1. CPT-CE activity was variable
from one specimen to another with a coefficient of variation of
about 50% in primary tumour and normal tissues. The mean values
for CPT-CE activity were 2.24 pmol min–1 mg–1 protein in primary
tumour tissue and 3.06 pmol min–1 mg protein–1 in normal colon
tissue (Table 1). CPT-CE activity was significantly higher in
normal tissue than in tumour tissue (P = 0.0041) (Figure 2). In 43
out of 53 primary tumours, CPT-CE activity ranged between 1 and
3 pmol min–1 mg protein–1, whereas the variability was greater
among normal tissue samples.
The ratio of CPT-CE activity between tumour and normal tissue
was evaluated to assess the degree of tumour-specific CPT-11 acti-
vation (Figure 3). Eighteen of 53 patients had a ratio above 1 and
among these 18 patients, 11 were suffering from Dukes’ C disease.
This distribution is significantly different from that observed in the
two other Dukes’ groups (P = 0.016, c2, ddl = 2).
The mean CPT-CE activity in liver metastases (n = 8) was
1.90 pmol min–1 mg protein–1 (range 0.42–4.17), which is compa-
rable to that observed in primary tumours (2.24) (P = 0.414,
dF = 59). CPT-CE activity in normal liver (n = 8) ranged from 2.05
to 8.17 pmol min–1 mg protein–1 and this was significantly higher
than in liver metastases (P = 0.009) (Figure 2). Consequently, the
ratio of CPT-CE activity between liver metastases and normal liver
ranged from 0.19 to 1.02 (mean 0.47).
No difference was observed in CPT-CE activity between the
normal liver and the normal colon (P = 0.094; dF = 59) (Figure 2).
Tumour CPT-CE activities were independent of the age and the
sex of the patient, the differentiation state of the tumour and the
stage of the disease.
Topo I activity
Mean, CV and median values of topo I activities in tumour and
normal colon tissues are summarized in Table 1. The coefficients
of variation in both normal and tumour tissues were high: 76% and
79% respectively. The distribution of topo I activity is illustrated
in Figure 4. Levels of topo I in the tumour ranged from 580 to
84 900 U mg protein–1. In 11 out of 53 tumours, topo I activity was
greater than 40 000 U mg protein–1. Topo I activity was signifi-
cantly different in primary tumour compared to normal tissue (P =
0.008, n = 53). Moreover, the topo I activity was significantly
lower in the liver metastases than in the normal liver (P = 0.003, n
= 8). Finally, topo I activity was similar in normal liver and the
normal colon (P = 0.708, dF = 59).
The ratio between tumour and normal tissue activities was
highly variable from one patient to another (Figure 5). Thirty-two
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of 53 patients showed a ratio above 1, and in 12 cases, the ratio
was above 5. So, a favourable gradient between the tumour and the
normal colon would be achieved in more than half of the patients.
Tumour topo I activities were independent of the age and the
sex of the patient, and the differentiation state of the tumour.
Figure 6 illustrates the distribution of topo I activity as a func-
tion of clinical stage of the disease (Dukes’ or metastases). Topo I
activity correlated inversely with clinical stage of the disease: the
mean topo I activity was lower in stage C than in stage A tumours
(P = 0.05, dF = 36). Moreover, in the Dukes’ C tumours (n = 28),
12 samples had a low topo I activity (< 10 000 U mg protein–1)
while ten had a very high activity (> 35 000 U mg protein–1),
suggesting a bimodal distribution. Assuming that the presence of
metastases is a step further in the progression of the disease, we
compared topo I activity in primary tumour and in liver metas-
tases. Topo I activity was significantly lower in liver metastases
than in primary tumour (P < 0.001, dF = 59), and significantly
lower in liver metastases than in Dukes’ C subgroup (P < 0.001,
dF = 34).
DISCUSSION
This study provides the first simultaneous analysis of both the
CPT-CE and the topo I activities in 53 patients with primary
colorectal carcinomas and eight patients with liver metastases.
Characterization of these enzymes in colorectal cancer is of
clinical interest because of their roles in the regulation of activity
and/or toxicity of CPT-11, one of the new agents active in
colorectal cancer (Rothenberg et al, 1996; Rougier et al, 1997).
Table 1 Enzyme activities in tumoural and normal colon and liver tissues
Colon tumour Colon Tumour vs Liver Normal Metastases
tissue normal metastases liver vs normal
tissue ratio tissue ratio
n = 53 n = 53 n = 8 n = 8
CPT-CE Mean 2.24 3.06 1.06 1.90 4.09 0.49
pmol min–1 C.V. (%) 46 51 98 73 45 68
mg protein–1 Median 1.81 2.93 0.74 1.48 3.47 0.42
Min 0.76 0.74 0.17 0.42 2.05 0.19
Max 5.77 7.33 5.77 4.17 8.17 1.02
Topo I Mean 25291 17339 3.40 8500 19250 0.47
U mg protein–1 C.V. (%) 76 79 139 63 57 52
Median 23200 17100 1.64 8700 15900 0.51
Min 580 500 0.09 1400 8600 0.08
Max 84900 64900 20 16800 36800 0.84
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To be active, CPT-11 must be converted by a carboxylesterase
into SN-38, which is a potent inhibitor of the topo I (Tanizawa et
al, 1994). Our study demonstrated an important variability in CPT-
CE activity in the 53 primary tumour specimens and that CPT-CE
activity was equal in primary and secondary colorectal tumours
and was only about two- to three-fold lower than in human normal
liver tissue. Although conversion of CPT-11 into SN-38 is likely to
occur in the major pharmacological sites, i.e. the liver in humans,
there may also be a local activation of CPT-11 in tumour tissue.
The local activation of CPT-11 is of potential importance because
of the different metabolic pathways between the hepatocytes and
the tumour cells. In the liver, CPT-11 can be inactivated by
cytochrome 3A4 in 7-ethyl-10[4-N-(5-aminopentanoic acid)-1-
piperidino]carbonyloxy-camptothecin or APC (Haaz et al, 1998),
which is not a substrate for human liver carboxylesterase (Rivory
et al, 1996). Moreover, SN-38 produced in hepatocytes is glucuro-
conjugated and thereby inactivated before excretion in the bile and
urine (Gupta et al, 1994; Rivory & Robert, 1995). A very different
metabolism occurs in a tumour cell. Neither the inactivation of the
CPT-11 by cytochrome 3A4 nor the glucuro-conjugation is likely
to occur in the tumour cells since the activity of these enzymes is
very low in colon tumour cells (Massaad et al, 1993; McKay et al,
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1993). Therefore, the anti-tumour effect of CPT-11 may be medi-
ated both by SN-38 produced in the liver and transported to the
tumour site by blood flow, and by SN-38 produced in the tumour
cells themselves. The relative contribution of these two amounts of
active drug is unknown. The importance of carboxylesterase acti-
vation of CPT-11 has suggested some strategies to enhance this
local activation by in vivo transfer of a human or rabbit liver
carboxylesterase c-DNA into tumours with concomitant local
administration of CPT-11 (Kojima et al, 1998; Danks et al, 1998).
Our study showed that the CPT-CE activity was similar in liver
and in normal colon. Moreover, the activity in the normal adjacent
colon mucosa was higher than in tumour in 65% of patients, in
agreement with the data of Lund-Pero et al (Lund-Pero et al,
1994). The administration of CPT-11 induced several side-effects,
among them acute and delayed diarrhoea. A local conversion of
CPT-11 to SN-38 by the CPT-CE present in normal colon cells
could be responsible of a local cytotoxic effect. Takasuma et al,
1996) evaluated the CPT-CE activity along the digestive tract and
demonstrated that carboxylesterase was lower in the colon than in
the ileum and jejunum. The mechanism of action of topo I
inhibitors requires the presence of a DNA synthesis (Creemers et
al, 1994) and cells constituting the colon epithelium have a high
mitotic index. In these conditions, even a low amount of SN-38
formed could mediate a significant cytotoxicity potentially respon-
sible for a diarrhoea.
Topo I activity is the second factor in the anti-tumour activity of
CPT-11. Topo I is a cellular target of CPT-11 and the sensitivity to
CPT-11 may be related to the topo I gene expression, the topo I
protein levels, the activity of the enzyme, and/or the formation of
drug stabilized cleavable complexes (Slichenmyer et al, 1993;
Creemers et al, 1994; Tanizawa et al, 1994). Our study constitutes
the most extensive series of primary colorectal tumours analysed
for topo I activity (n = 53) and includes eight liver metastases. This
activity was highly variable in tumour and normal adjacent tissue.
The variability of the topo I activity in tumour was higher than that
observed by McLeod et al (1994) and Husain et al (1994). It was
comparable to that found by Bronstein et al (1996) in different
tumour types. Our data demonstrated that topo I activity was also
higher in the tumour than in adjacent normal tissue. This differ-
ence may contribute to the favourable therapeutic index of CPT-
11. The ratio of tumour compared to normal topo I activity is
different from that reported by Husain et al (1994) and Giovanella
et al (1989) who showed, in all cases tested, an 11- to 40-fold
increase in catalytic activity of topo I in tumour compared to
matched normal controls, leading to the expectation of a high
response rate with CPT-11. Our results showed that only some
tumours had very high levels of topo I (11 of 53 patients with
tumoural topo I activity upper than 40 000 U mg protein–1) and/or
very high ratio between tumour and normal tissues (12 of 53
patients with a ratio above 5). Moreover, topo I activity decreased
with increasing clinical stage of disease, mainly in liver metastases
in which it was significantly lower than in primary colon tumours.
This observation is in contrast with the data reported by
Giovanella (1989). The difference in the distribution of Dukes’
stages among the population of patients studied and the determina-
tion of the topo I copy number instead of a topo I activity could
explain the discrepancies between these two studies. Our study
demonstrated that both the CPT-CE and the topo I activities are
widely variable in the malignant and the normal tissue of patients
with colorectal carcinomas. This high variability could influence
the susceptibility of these tumours to CPT-11-based chemotherapy.
Clinical studies are in progress in our institution to explore the
correlation between tumour enzyme activities and clinical
outcome in patients with metastatic colon cancer treated with CPT-
11-based chemotherapy.
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